论文部分内容阅读
目的探讨C57/BL6J小鼠重复多次尾静脉输注人脐带间充质干细胞后的免疫反应和毒性。方法将SPF级别的32只C57/BL6J小鼠随机分为阴性对照组、细胞移植组,每组16只,雌雄各半,细胞移植组小鼠尾静脉注射分离培养的第5代人脐带间充质干细胞,一次5×106/只,每周注射一次,连续注射4周;阴性对照组每次注射相同容积的PBS。注射后后观察小鼠的一般症状,末次注射后1周、4周进行血细胞计数、血生化、免疫反应指标、脏器质量测定和组织病理学检查。结果细胞移植组小鼠血细胞计数、血生化、脏器重量和脏器系数与对照组无显著性差异(P>0.05),脏器组织病理学在光镜下检查结果与对照组无形态学差别,以及免疫结果测定(T细胞亚群CD3+、CD4+、CD8+及CD4+/CD8+)与对照组无显著性差异(P>0.05)。结论人脐带间充质干细胞重复多次尾静脉输注C57/BL6J小鼠是安全可行的,对受者无明显免疫反应和毒副作用。
Objective To investigate the immune response and toxicity of C57 / BL6J mice after repeated intravenous infusion of human umbilical cord mesenchymal stem cells. Methods Thirty-two C57 / BL6J mice of SPF grade were randomly divided into negative control group, cell transplantation group, 16 in each group, male and female in half, cell transplantation group mice were injected intravenously Massive stem cells, a 5 × 106 / only, once a week, continuous injection of 4 weeks; negative control group each injection of the same volume of PBS. After injection, the general symptoms of the mice were observed. The blood counts, blood biochemistry, immune response indexes, organ quality and histopathological examination were observed 1 week and 4 weeks after the last injection. Results There was no significant difference in blood count, blood biochemistry, organ weight and organ coefficient between the mice in the cell transplantation group and the control group (P> 0.05). There was no difference between the histopathological examination and the control group (T cell subsets CD3 +, CD4 +, CD8 + and CD4 + / CD8 +) were not significantly different from the control group (P> 0.05). Conclusion Human umbilical cord mesenchymal stem cells were transplanted into tail vein repeatedly in C57 / BL6J mice for several times. It is safe and feasible to treat C57 / BL6J mice without obvious immunological reaction and toxicity.